Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2004;109:1660-1667
Published online before print March 15, 2004, doi: 10.1161/01.CIR.0000124067.35915.E0
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
109/13/1660    most recent
01.CIR.0000124067.35915.E0v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, J.
Right arrow Articles by Li, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, J.
Right arrow Articles by Li, J.
Related Collections
Right arrow Valvular heart disease
Right arrow Other Vascular biology
Right arrow Apoptosis
Right arrow Ischemic biology - basic studies

(Circulation. 2004;109:1660-1667.)
© 2004 American Heart Association, Inc.


Basic Science Reports

PR39 Inhibits Apoptosis in Hypoxic Endothelial Cells

Role of Inhibitor Apoptosis Protein-2

Jiaping Wu, MD; Cherie Parungo, MD*; Guifu Wu, MD, PhD*; Peter M. Kang, MD; Roger J. Laham, MD; Frank W. Sellke, MD; Michael Simons, MD; Jian Li, MD, PhD

From the Angiogenesis Research Center, Divisions of Cardiology (J.W., C.P., G.W., P.M.K., R.J.L., J.L.) and Cardiothoracic Surgery (F.W.S.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass, and Section of Cardiology, Dartmouth-Hitchcock Medical Center, Dartmouth Medical School, Hanover, NH (M.S.).

Correspondence to Jian Li, MD, PhD, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA 02215. E-mail jli{at}bidmc.harvard.edu

Received March 7, 2003; de novo received October 20, 2003; revision received December 15, 2003; accepted December 30, 2003.

Background— PR39 is a proline- and arginine-rich peptide implicated in wound healing and myocardial ischemia protection. To determine the potential mechanisms of PR39 in ischemia, we examined the role of PR39 in hypoxia-induced apoptosis in vascular endothelial cells.

Methods and Results— Hypoxia results in an increase of apoptosis in bovine aortic endothelial cells (BAECs), as determined by terminal deoxynucleotidyl transferase–mediated dUTP biotin nick-end labeling (TUNEL) analysis and caspase-3 activity. Hypoxia induced 66.2±2.7% TUNEL-positive cells, whereas in the presence of synthesized PR39 peptide, TUNEL-positive cells were reduced to 29.6±1.9% (P<0.05). After 24 hours of hypoxia, the addition of PR39 reduced caspase-3 activity to 3.17±0.47 pMol/min from 10.52±0.55 pMol/min in hypoxic BAECs. Moreover, PR39 increased inhibitor of apoptosis protein-2 (IAP-2) gene and protein expression by 3-fold in a time- and dose-dependent manner. The induction of IAP-2 by PR39 conferred an increase in IAP-2 gene transcription and IAP-2 mRNA stability. Furthermore, inhibiting IAP-2 with second mitochondria-derived activator of caspase (Smac) and with small interfering RNA targeting IAP-2 abrogated the ability of PR39 to reduce caspase-3 activity.

Conclusions— We provide the first direct evidence for PR39 as an antiapoptotic factor in endothelial cells during hypoxia. These data suggest that PR39 inhibits hypoxia-induced apoptosis and decreases caspase-3 activity in endothelial cells through an increase of IAP-2 expression.


Key Words: peptides • hypoxia • apoptosis • cells, endothelial




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
E. W. Childs, B. Tharakan, N. Byrge, J. H. Tinsley, F. A. Hunter, and W. R. Smythe
Angiopoietin-1 inhibits intrinsic apoptotic signaling and vascular hyperpermeability following hemorrhagic shock
Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H2285 - H2295.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. J. Post, K. Sato, M. Murakami, J. Bao, D. Tirziu, J. D. Pearlman, and M. Simons
Adenoviral PR39 improves blood flow and myocardial function in a pig model of chronic myocardial ischemia by enhancing collateral formation
Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R494 - R500.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Tomasinsig, B. Skerlavaj, N. Papo, B. Giabbai, Y. Shai, and M. Zanetti
Mechanistic and Functional Studies of the Interaction of a Proline-rich Antimicrobial Peptide with Mammalian Cells
J. Biol. Chem., January 6, 2006; 281(1): 383 - 391.
[Abstract] [Full Text] [PDF]